Novel aspects on insulin resistance: A quick overview

Endocrinologist

Volumn 19, Issue 6, 2009, Pages 302-305

  Anderwald, Christian ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Adipotoxicity; Free fatty acids; Insulin signal transduction; Leptin; Type 2 diabetes mellitus

Indexed keywords

ADIPONECTIN; GHRELIN; INSULIN; INSULIN RECEPTOR; LEPTIN; OBESTATIN; RESISTIN; RETINOL;

GLUCOSE TRANSPORT; HORMONE ACTION; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC DISORDER; REVIEW; SIGNAL TRANSDUCTION;

EID: 74549121361     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/TEN.0b013e3181c0479d     Document Type: Review

References (55)

1. Cheatham B, Kahn CR. Insulin action and the insulin signaling network. Endocr Rev. 1995;16:117-142.
2. DeFronzo RA. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes. 1988;37:667-687.
3. Krebs M, Krssak M, Bernroider E, et al. Mechanism of amino acid-induced skeletal muscle insulin resistance in humans. Diabetes. 2002;51:599-605.
4. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)-erratum appears in Lancet. 1998;352:1557-. Lancet. 1998;352:854-865.
5. Stadler M, Auinger M, Anderwald C, et al. Long-term mortality and incidence of renal dialysis and transplantation in type 1 diabetes mellitus. J Clin Endocrinol Metab. 2006;91:3814-3820.
6. Cheatham B. GLUT4 and company: SNAREing roles in insulin-regulated glucose uptake. Trends Endocrinol Metab. 2001;11:356-361.
7. Krook A, Bjornholm M, Galuska D, et al. Characterization of signal transduction and glucose transport in skeletal muscle from type 2 diabetic patients. Diabetes. 2000;49:284-292.
8. Previs SF, Withers DJ, Ren JM, et al. Contrasting effects of IRS-1 versus IRS-2 gene disruption on carbohydrate and lipid metabolism in vivo. J Biol Chem. 2000;275:38990-38994.
9. Cai D, Dhe-Paganon S, Melendez PA, et al. Two new substrates in insulin signaling, IRS5/DOK4 and IRS6/DOK5. J Biol Chem. 2003;278:25323-25330.
10. Tremblay F, Marette A. Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle cells. J Biol Chem. 2001;276:38052-38060.
11. Krebs M, Brunmair B, Brehm A, et al. The mammalian target of rapamycin pathway regulates nutrient-sensitive glucose uptake in man. Diabetes. 2007; 56:1600-1607.
12. Cusi K, Maezono K, Osman A, et al. Insulin resistance differentially affects the PI 3-kinase-and MAP kinase-mediated signaling in human muscle. J Clin Invest. 2000;105:311-320.
13. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;7:1595-1607.
14. Anderwald C, Bernroider E, Krs?s?ák M, et al. Effects of insulin treatment in type 2 diabetic patients on intracellular lipid content in liver and skeletal muscles. Diabetes. 2002;51:3025-3032.
15. Krssak M, Brehm A, Bernroider E, et al. Alterations in postprandial hepatic glycogen metabolism in type 2 diabetes. Diabetes. 2004;53:3048-3056.
16. Kautzky-Willer A, Krssak M, Winzer C, et al. Increased intramyocellular lipid concentration identifies impaired glucose metabolism in women with previous gestational diabetes. Diabetes. 2003;52:244-251.
17. Bernroider E, Brehm A, Krssak M, et al. The role of intramyocellular lipids during hypoglycemia in patients with intensively treated type 1 diabetes. J Clin Endocrinol Metab. 2005;90:5559-5565.
18. Anderwald C, Roden M. Adipotoxicity and the insulin resistance syndrome. Pediatr Endocrinol Rev. 2004;1:310-319.
19. Krs?s?ák M, Falk Petersen K, Dresner A, et al. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia. 1999;42:113-116.
20. Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes. 1995;44:863-870.
21. Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care. 1990;13:610-630.
22. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782-787.
23. Howard G, O'Leary DH, Zaccaro D, et al. Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Circulation. 1996;93:1809-1817.
24. Wohlin M, Sundstrom J, Arnlov J, et al. Impaired insulin sensitivity is an independent predictor of common carotid intima-media thickness in a population sample of elderly men. Atherosclerosis. 2003;170:181-185.
25. Anderwald C, Pfeiler G, Nowotny P, et al. Glucose turnover and intima media thickness of internal carotid artery in type 2 diabetes offspring. Eur J Clin Invest. 2008;38:227-237.
26. Baumgartner-Parzer SM, Waldhausl WK. The endothelium as a metabolic and endocrine organ: its relation with insulin resistance. Exp Clin Endocrinol Diabetes. 2001;109(suppl 2):S166-S179.
27. Yki-Järvinen H, Utriainen T. Insulin-induced vasodilatation: physiology or pharmacology? Diabetologia. 1998;41:369-379.
28. Hills SA, Balkau B, Coppack SW, et al. The EGIR-RISC STUDY (The European group for the study of insulin resistance: relationship between insulin sensitivity and cardiovascular disease risk): I. Methodology and objectives. Diabetologia. 2004;47:566-570.
29. Wick MC, Anderwald C, Weiss RJ, et al. Radiological progression of joint damage in a longitudinal cohort of early DMARD-treated rheumatoid arthritis patients followed for 10 years. Scand J Rheumatol. 2004;33:162-166.
30. Air EL, Benoit SC, Clegg DJ, et al. Insulin and leptin combine additively to reduce food intake and body weight in rats. Endocrinology. 2002;143:2449-2452.
31. Artwohl M, Roden M, Holzenbein T, et al. Modulation by leptin of proliferation and apoptosis in vascular endothelial cells. Int J Obes Relat Metab Disord. 2002;26:577-580.
32. Ceddia RB, Lopes G, Souza HM, et al. Acute effects of leptin on glucose metabolism of in situ rat perfused livers and isolated hepatocytes. Int J Obes Relat Metab Disord. 1999;23:1207-1212.
33. Müller G, Ertl J, Gerl M, et al. Leptin impairs metabolic actions of insulin in isolated rat adipocytes. J Biol Chem. 1997;272:10585-10593.
34. Havel PJ. Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. Diabetes. 2004;53(suppl 1):S143-S151.
35. Tschöp M, Weyer C, Tataranni PA, et al. Circulating ghrelin levels are decreased in human obesity. Diabetes. 2001;50:707-709. (Pubitemid 32242624)
36. Bado A, Levasseur S, Attoub S, et al. The stomach is a source of leptin. Nature. 1998;394:790-793.
37. Anderwald-Stadler M, Krebs M, Promintzer M, et al. Plasma obestatin is lower at fasting and not suppressed by insulin in insulin-resistant humans. Am J Physiol Endocrinol Metab. 2007;293:E1393-E1398.
38. Inzucchi SE, McGuire DK. New drugs for the treatment of diabetes. Part II: incretin-based therapy and beyond. Circulation. 2008;117:574-584.
39. Bajaj M, Suraamornkul S, Kashyap S, et al. Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes. J Clin Endocrinol Metab. 2004;89:4649-4655.
40. Nagaev I, Smith U. Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem Biophys Res Commun. 2001;285:561-564.
41. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409:307-312.
42. Promintzer M, Krebs M, Todoric J, et al. Insulin resistance is unrelated to circulating retinol binding protein and protein C inhibitor. J Clin Endocrinol Metab. 2007;92:4306-4312.
43. Stadler M, Anderwald C, Karer T, et al. Increased plasma amylin in type 1 diabetic patients after kidney and pancreas transplantation: a sign of impaired beta-cell function? Diabetes Care. 2006;29:1031-1038.
44. Thompson RG, Pearson L, Schoenfeld SL, et al. Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes Group. Diabetes Care. 1998;21:987-993.
45. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237:E214-E223.
46. Hother-Nielsen O, Henriksen JE, Holst JJ, et al. Effects of insulin on glucose turnover rates in vivo: isotope dilution versus constant specific activity technique. Metabolism. 1996;45:82-91.
47. Ferrannini E, Vichi S, Beck-Nielsen H, et al. Insulin action and age. European Group for the Study of Insulin Resistance (EGIR). Diabetes. 1996;45:947-953.
48. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes. 1997;46:3-10.
49. Perseghin G, Ghosh S, Gerow K, et al. Metabolic defects in lean nondiabetic offspring of NIDDM parents: a cross-sectional study. Diabetes. 1997;46: 1001-1009.
50. Shah P, Vella A, Basu A, et al. Effects of free fatty acids and glycerol on splanchnic glucose metabolism and insulin extraction in nondiabetic humans. Diabetes. 2002;51:301-310.
51. Staehr P, Hother-Nielsen O, Levin K, et al. Assessment of hepatic insulin action in obese type 2 diabetic patients. Diabetes. 2001;50:1363-1370.
52. Mari A, Pacini G, Murphy E, et al. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care. 2001;24:539-548.
53. Stumvoll M, Mitrakou A, Pimenta W, et al. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care. 2000;23: 295-301. (Pubitemid 30131733)
54. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22:1462-1470.
55. Anderwald C, Anderwald-Stadler M, Promintzer M, et al. The Clamp-Like Index: a novel and highly sensitive insulin sensitivity index to calculate hyperinsulinemic clamp glucose infusion rates from oral glucose tolerance tests in nondiabetic subjects. Diabetes Care. 2007;30:2374-2380.